Home European Commission Grants Marketing Authorization for Gilead's...
 

Keywords :   


European Commission Grants Marketing Authorization for Gilead's...

2014-11-19 12:58:48| Biotech - Topix.net

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Harvoni , the first once-daily single tablet regimen to treat the majority of chronic hepatitis C genotype 1 and 4 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir with the nucleotide analog polymerase inhibitor sofosbuvir , approved by the European Commission under the tradename Sovaldi in January 2014.

Tags: marketing european commission grants

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
24.111000 15
24.11 nike soccer usa national team uniform
24.1160266
24.11 1
24.11
24.11GREATEST HITS ALTER EGO EGOIST
24.11(ALINCO)
24.11[]34
More »